Innovation

Great Power offers reliable solutions in the field of commercial battery storage systems, addressing the growing global need for scalable and efficient energy storage. Their Magna-UTL-373 DC Outdoor Battery System is designed with high safety standards, featuring UL9540A unit-level certification. This prevents battery cell thermal runaway and supports direct series connection with PCS units without circulation current issues. Such safety attributes are particularly valuable for industrial-scale applications like utilities, solar farms, and large commercial facilities.

Long Service Life and Flexible Installation

One of the standout features of Great Power’s commercial battery storage systems is the enhanced service life. The Magna-UTL-373 uses a liquid cooling system that keeps temperature variations within 2°C, increasing battery lifespan by 30%. Additionally, each unit is under 4 tons, making it easy to hoist and install on-site. For B2B customers in regions like North America, Europe, or Southeast Asia, this flexible installation capability reduces overall deployment costs and timelines.

Supporting Reliable Power for Utility and Industrial Use

With over 20 years of experience in battery innovation, Great Power has built commercial battery storage systems that support zero-accident operation records across 50+ countries. Their solutions replace bulkier container units and offer modular designs, simplifying maintenance and scalability. Whether for schools, factories, or energy service providers, these systems meet the diverse demands of commercial energy storage with reliability and precision.

Conclusion

Great Power demonstrates a strong ability to deliver commercial battery storage systems that are safe, modular, and scalable. Their advanced battery architecture ensures stable power delivery for B2B applications worldwide. For companies seeking dependable and efficient storage solutions, these systems offer a practical and future-ready choice.

"When you do come to realise that there's something wrong with your bike, it is going to be too late because we are talking about a very, very fast-developing fire that you will have not a chance to get past," says a sister in mourning.

Ehsia Johnson-Mall still struggles to come to terms with the loss of her sister, Natasha, at the age of 27 in November.

Natasha, along with her partner, 24-year-old Karlo Bogdan, died at the home they shared in Coventry after a battery Karlo had fitted to an e-bike caught fire.

Now, Ms Johnson-Mall is trying to raise awareness of the dangers of using home conversion kits to replace e-bike batteries.

The deaths of the couple were ruled as accidental at an inquest in February.

An investigation by West Midlands Fire Service (WMFS) said the blaze started when the battery ignited and "rapidly escalated into an intense blaze".

It said that over the past two years it had seen a 50% increase in fires caused by lithium-ion batteries, which are often found on e-bikes.

WMFS said it was concerned that people underestimated the dangers posed, especially if the batteries degrade.

"The battery that we believe Karlo had purchased was actually subject to a product recall before he'd actually purchased it due to… other fires that have happened nationally," said fire investigation officer Annette Carrington. "It's obvious that this risk was unknown to Karlo."

It is thought that nationally, 15 people have died in fires caused by e-bike batteries.

Ms Johnson-Mall believes the night the fire that killed her sister broke out was the first night the bike was left charging in the hall – and is determined to make people aware of the risks.

"I know Karlo would be absolutely devastated at himself," she said. "Knowing that he had an item that was his possession that had caused this fatality."

A memorial bench has been placed outside Natasha and Karlo's home, but Ms Johnson-Mall wants her sister's legacy to be that no other lives are lost in the same way.

"The fact that we've got to sit on a bench with her name on it and not sit with her on a garden bench is just unfair beyond belief."

Ms Carrington agrees that people need to understand the dangers.

"Imagine 70 or 80 fireworks going off at one point," she explained. "I would never advise anyone to carry out their own conversion.

"Is a life worth the risk? I would say no."

Patients with advanced skin cancer could be fast-tracked to take part in a "revolutionary" trial of a new cancer vaccine.

The needle-free injection boosts the immune system's response and helps it attack and recognise cancer cells to help stop the disease returning.

The trial is being coordinated by the Southampton Clinical Trials Unit, which is based at the city's university, and is aiming to expand the number of patients able to take part.

Melanoma is the fifth most common cancer in the UK and accounts for about 4% of all new cancer cases but research shows it is on the rise.

The NHS will work with Oxford-based life sciences company Scancell to widen access for patients at seven sites across England, including in Southampton, with the first patients set to be referred in May.

The work is being done as part of the NHS's Cancer Vaccine Launch Pad (CVLP), a trial to help find treatments for patients at their nearest participating NHS site.

Grandfather-of-four Paul Thomas, 63, from New Milton, Hampshire, was first diagnosed with advanced skin cancer in 2017 and the disease kept returning following treatment.

He was put on the trial in July and said he felt lucky to be included.

"Thankfully I was still quite fit and since I've been on it, my tumours have all shrunk. Every time I go for a scan they seem to be shrinking, which is very exciting," Mr Thomas said.

"I'm really hoping for total eradication of my cancer, as opposed to being put in remission and I'm feeling optimistic."

Potential participants first need a blood test to determine their tissue type. It looks at genes that control how the immune system works which varies from person to person.

Prof Gareth Griffiths, director of the Southampton Clinical Trials Unit, said: "We hope that by being part of this ground-breaking programme we can help to increase referrals for this trial and give more patients with advanced melanoma access to new, potentially life-saving treatments."

X